- RecruitingPHASE3
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
This study looks at a new drug, 177Lu-TLX591, for men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. It compares this new drug combined with standard treatments to standard treatments alone.
For: Metastatic Castration-resistant Prostate CancerUnited States · Australia · Canada - Active not recruitingPHASE3
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
This study looks at a new drug, abemaciclib, combined with standard treatment for prostate cancer that has spread. We want to see if this combination can stop the cancer from getting worse for longer in men whose cancer is still responding to hormone therapy.
For: Prostatic Neoplasms · Neoplasm Metastasis · Urogenital NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE3
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
This study is testing a new drug, AZD2265, for men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. We want to see if AZD2265 works better than current treatments at slowing down cancer growth and helping men live longer.
For: Metastatic Castration-resistant Prostate CancerUnited States · Australia · Austria - Active not recruitingPHASE3
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
This study looks at a new treatment, [Lu-177]-PNT2002, for advanced prostate cancer that has spread and isn't responding to standard hormone therapy. It compares this new treatment with existing hormone therapies to see if it can slow down cancer growth.
For: Metastatic Castration-Resistant Prostate CancerUnited States · Canada · France - Active not recruitingPHASE3
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
This study is looking at a new medicine called Xaluritamig for men with advanced prostate cancer that has stopped responding to standard hormone therapy. It compares Xaluritamig to existing treatments like Cabazitaxel or other hormone therapies, to see which is more effective at helping men live longer.
For: Metastatic Castration-resistant Prostate CancerUnited States · Australia · Austria - RecruitingPHASE1, PHASE2
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
This study is testing new treatments, alone or in combination, for advanced prostate cancer that has spread and no longer responds to hormone therapy. Researchers want to see if these treatments are safe and effective in helping men with this condition.
For: Castration-Resistant Prostatic Cancer · MetastasisUnited States · Argentina · Australia - Active not recruitingPHASE2, PHASE3
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy
This study, called STAMPEDE, looks for better ways to treat prostate cancer that is spreading or has a high chance of spreading. It tests new treatments against standard ones to help men live longer and have a better quality of life.
For: Prostate CancerSwitzerland · United Kingdom - RecruitingPHASE3
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
This study looks at a new drug, BMS-986365, for men with prostate cancer that has spread and is no longer responding to hormone treatment. We want to see if it works better and is safer than standard treatments chosen by doctors.
For: Metastatic Castration-resistant Prostate CancerUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
This study looks at new combinations of medicines for men with prostate cancer that has spread. It checks if combining a new drug, tulmimetostat, with existing treatments like darolutamide or abiraterone is safe and works well. The goal is to find better ways to treat this type of cancer.
For: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)United States · Australia · Brazil